RxDoctor Payments Data

Sydney Lahre

Psychiatric/Mental Health · Newark, OHNPI 1508555335

Payments from drug & device makers

$1,758in general payments, 2019–2025

Across 102 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$353
  • AbbVie$302
  • Johnson & Johnson$298
  • Alkermes, Inc.$205
  • E.r. Squibb & Sons, L.L.C.$196
  • Otsuka America Pharmaceutical, Inc.$155
  • plus $249 from 5 others

What the payments were for

  • Food & beverage$1,51986%
  • Education$23914%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,758 in reported general payments places this provider in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

See all psychiatric/mental health providers in Ohio

Medicare billing

Part B allowed, 2024
$24,352
Medicare patients
52
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate160$526,866
IngrezzaValbenazine Tosylate31$360,488
Invega TrinzaPaliperidone Palmitate21$195,257
AustedoDeutetrabenazine17$116,092
Austedo XrDeutetrabenazine12$84,356
RexultiBrexpiprazole52$76,168
AristadaAripiprazole Lauroxil18$53,264
VraylarCariprazine Hcl28$51,306
Abilify MaintenaAripiprazole18$48,679
TrintellixVortioxetine Hydrobromide29$22,200
Lurasidone Hcl62$19,005
FetzimaLevomilnacipran Hcl19$9,374
Aripiprazole88$8,526
Paliperidone ErPaliperidone53$7,478
Haloperidol Decanoate95$4,446

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$298$722,123181 claims
Neurocrine Biosciences, Inc.Ingrezza$49$360,48831 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$353$200,44929 claims
Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena$155$124,84770 claims
AbbVieVraylar, Fetzima$302$60,68047 claims
Alkermes, Inc.Aristada$205$53,26418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,808 psychiatric/mental health providers in Ohio.

Other psychiatric/mental health in Newark

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →